Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| arm 1 | EXPERIMENTAL | darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir |
| arm 2 | ACTIVE_COMPARATOR | darunavir, ritonavir, emtricitabine/tenofovir |
| Name | Type | Description |
|---|---|---|
| raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine | DRUG | raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD. |
| darunavir; ritonavir; emtricitabine/tenofovir | DRUG | darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD. |
Inclusion Criteria: * Patients with acute or primary HIV-1 infection * Acute infection: negative or slightly positive Elisa, with negative or incomplete western-blot (0 or 1 antibody) and positive HIV-RNA and/or positive Ag p24. * Primary infection: positive Elisa with incomplete Western-blot (≥ 2 ...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
This combination regimen is used to treat HIV-1 infection. It combines five antiretroviral agents from different classes: raltegravir, maraviroc, darunavir, ritonavir, and tenofovir/emtricitabine. The regimen was studied in a Phase 3 trial in France in adults with primary HIV-1 infection, which is the early stage after initial infection.
Gilead Sciences, Inc. (ticker GILD) is the developer associated with this regimen. The combination brings together several small molecule antiretroviral agents, including tenofovir/emtricitabine, which is a Gilead product. The regimen was evaluated in a Phase 3 study conducted in France.
The regimen has been studied in a Phase 3 clinical trial, which is now completed. It is an investigational combination for HIV-1 infection and is not described here as an approved product. The Phase 3 trial enrolled 90 participants and was active controlled.
The regimen was studied in NCT01033760, titled Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM). This Phase 3 trial enrolled 90 adults aged 18 years and older with HIV-1 infection in France. It was randomized, active controlled, and has been completed.
The regimen combines five small molecule antiretroviral agents that act on different steps of the HIV-1 lifecycle. Raltegravir is an integrase inhibitor, maraviroc is a CCR5 antagonist, darunavir is a protease inhibitor boosted by ritonavir, and tenofovir/emtricitabine are nucleoside/nucleotide reverse transcriptase inhibitors. Combining classes targets the virus at multiple points.